Ryan T Borne1, Frederick A Masoudi1, Jeptha P Curtis2,3, Matthew M Zipse1, Amneet Sandhu1, Jonathan C Hsu4, Pamela N Peterson1,5. 1. Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora. 2. Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. 3. Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut. 4. Section of Cardiac Electrophysiology, Division of Cardiology, University of California, San Diego, La Jolla. 5. Division of Cardiology, Denver Health Hospital, Denver, Colorado.
Abstract
Importance: Frequent right ventricular (RV) pacing can cause and exacerbate heart failure. Cardiac resynchronization therapy (CRT) has been shown to be associated with improved outcomes among patients with reduced left ventricular ejection fraction who need frequent RV pacing, but the patterns of use of CRT vs dual chamber (DC) devices and the associated outcomes among these patients in clinical practice is not known. Objective: To assess outcomes, variability in use of device type, and trends in use of device type over time among patients undergoing implantable cardioverter defibrillator (ICD) implantation who were likely to require frequent RV pacing but who did not have a class I indication for CRT. Design, Setting, and Participants: This retrospective cohort study used the National Cardiovascular Data Registry (NCDR) ICD Registry. A total of 3100 Medicare beneficiaries undergoing first-time implantation of CRT defibrillator (CRT-D) or DC-ICD from 2010 to 2016 who had a class I or II guideline ventricular bradycardia pacing indication but not a class I indication for CRT were included. Data were analyzed from August 2018 to October 2019. Exposures: Implantation of a CRT-D or DC-ICD. Main Outcomes and Measures: All-cause mortality, heart failure hospitalization, and complications were ascertained from Medicare claims data. Multivariable Cox proportional hazards models and Fine-Gray models were used to evaluate 1-year mortality and heart failure hospitalization, respectively. Multivariable logistic regression was used to evaluate 30-day and 90-day complications. All models accounted for clustering. The median odds ratio (MOR) was used to assess variability and represents the odds that a randomly selected patient receiving CRT-D at a hospital with high implant rates would receive CRT-D if they had been treated at a hospital with low CRT-D implant rates. Results: A total of 3100 individuals were included. The mean (SD) age was 76.3 (6.4) years, and 2500 (80.6%) were men. The 1698 patients (54.7%) receiving CRT-D were more likely than those receiving DC-ICD to have third-degree atrioventricular block (828 [48.8%] vs 432 [30.8%]; P < .001), nonischemic cardiomyopathy (508 [29.9%] vs 255 [18.2%]; P < .001), and prior heart failure hospitalizations (703 [41.4%] vs 421 [30.0%]; P < .001). Following adjustment, CRT-D was associated with lower 1-year mortality (hazard ratio [HR], 0.70; 95% CI, 0.57-0.87; P = .001) and heart failure hospitalization (subdistribution HR, 0.77; 95% CI, 0.61-0.97; P = .02) and no difference in complications compared with DC-ICD. Hospital variation in use of CRT was present (MOR, 2.00), and the use of CRT in this cohort was higher over time (654 of 1351 [48.4%] in 2010 vs 362 of 594 [60.9%] in 2016; P < .001). Conclusions and Relevance: In this cohort study of older patients in contemporary practice undergoing ICD implantation with a bradycardia pacing indication but without a class I indication for CRT, CRT-D was associated with better outcomes compared with DC devices. Variability in use of device type was observed, and the rate of CRT implantation increased over time.
Importance: Frequent right ventricular (RV) pacing can cause and exacerbate heart failure. Cardiac resynchronization therapy (CRT) has been shown to be associated with improved outcomes among patients with reduced left ventricular ejection fraction who need frequent RV pacing, but the patterns of use of CRT vs dual chamber (DC) devices and the associated outcomes among these patients in clinical practice is not known. Objective: To assess outcomes, variability in use of device type, and trends in use of device type over time among patients undergoing implantable cardioverter defibrillator (ICD) implantation who were likely to require frequent RV pacing but who did not have a class I indication for CRT. Design, Setting, and Participants: This retrospective cohort study used the National Cardiovascular Data Registry (NCDR) ICD Registry. A total of 3100 Medicare beneficiaries undergoing first-time implantation of CRT defibrillator (CRT-D) or DC-ICD from 2010 to 2016 who had a class I or II guideline ventricular bradycardia pacing indication but not a class I indication for CRT were included. Data were analyzed from August 2018 to October 2019. Exposures: Implantation of a CRT-D or DC-ICD. Main Outcomes and Measures: All-cause mortality, heart failure hospitalization, and complications were ascertained from Medicare claims data. Multivariable Cox proportional hazards models and Fine-Gray models were used to evaluate 1-year mortality and heart failure hospitalization, respectively. Multivariable logistic regression was used to evaluate 30-day and 90-day complications. All models accounted for clustering. The median odds ratio (MOR) was used to assess variability and represents the odds that a randomly selected patient receiving CRT-D at a hospital with high implant rates would receive CRT-D if they had been treated at a hospital with low CRT-D implant rates. Results: A total of 3100 individuals were included. The mean (SD) age was 76.3 (6.4) years, and 2500 (80.6%) were men. The 1698 patients (54.7%) receiving CRT-D were more likely than those receiving DC-ICD to have third-degree atrioventricular block (828 [48.8%] vs 432 [30.8%]; P < .001), nonischemic cardiomyopathy (508 [29.9%] vs 255 [18.2%]; P < .001), and prior heart failure hospitalizations (703 [41.4%] vs 421 [30.0%]; P < .001). Following adjustment, CRT-D was associated with lower 1-year mortality (hazard ratio [HR], 0.70; 95% CI, 0.57-0.87; P = .001) and heart failure hospitalization (subdistribution HR, 0.77; 95% CI, 0.61-0.97; P = .02) and no difference in complications compared with DC-ICD. Hospital variation in use of CRT was present (MOR, 2.00), and the use of CRT in this cohort was higher over time (654 of 1351 [48.4%] in 2010 vs 362 of 594 [60.9%] in 2016; P < .001). Conclusions and Relevance: In this cohort study of older patients in contemporary practice undergoing ICD implantation with a bradycardia pacing indication but without a class I indication for CRT, CRT-D was associated with better outcomes compared with DC devices. Variability in use of device type was observed, and the rate of CRT implantation increased over time.
Authors: Fred M Kusumoto; Mark H Schoenfeld; Coletta Barrett; James R Edgerton; Kenneth A Ellenbogen; Michael R Gold; Nora F Goldschlager; Robert M Hamilton; José A Joglar; Robert J Kim; Richard Lee; Joseph E Marine; Christopher J McLeod; Keith R Oken; Kristen K Patton; Cara N Pellegrini; Kimberly A Selzman; Annemarie Thompson; Paul D Varosy Journal: J Am Coll Cardiol Date: 2018-11-06 Impact factor: 24.094
Authors: Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Cynthia M Tracy; Andrew E Epstein; Dawood Darbar; John P DiMarco; Sandra B Dunbar; N A Mark Estes; T Bruce Ferguson; Stephen C Hammill; Pamela E Karasik; Mark S Link; Joseph E Marine; Mark H Schoenfeld; Amit J Shanker; Michael J Silka; Lynne Warner Stevenson; William G Stevenson; Paul D Varosy Journal: J Am Coll Cardiol Date: 2012-12-19 Impact factor: 24.094
Authors: Frederick A Masoudi; Xiaojuan Mi; Lesley H Curtis; Pamela N Peterson; Jeptha P Curtis; Gregg C Fonarow; Stephen C Hammill; Paul A Heidenreich; Sana M Al-Khatib; Jonathan P Piccini; Laura G Qualls; Adrian F Hernandez Journal: Ann Intern Med Date: 2014-05-06 Impact factor: 25.391
Authors: Lucas N Marzec; Pamela N Peterson; Haikun Bao; Jeptha P Curtis; Frederick A Masoudi; Paul D Varosy; Steven M Bradley Journal: JAMA Cardiol Date: 2017-05-01 Impact factor: 14.676
Authors: Frederick A Masoudi; Angelo Ponirakis; James A de Lemos; James G Jollis; Mark Kremers; John C Messenger; John W M Moore; Issam Moussa; William J Oetgen; Paul D Varosy; Robert N Vincent; Jessica Wei; Jeptha P Curtis; Matthew T Roe; John A Spertus Journal: J Am Coll Cardiol Date: 2016-12-23 Impact factor: 24.094
Authors: Anne B Curtis; Seth J Worley; Philip B Adamson; Eugene S Chung; Imran Niazi; Lou Sherfesee; Timothy Shinn; Martin St John Sutton Journal: N Engl J Med Date: 2013-04-25 Impact factor: 91.245
Authors: Juan Merlo; Basile Chaix; Henrik Ohlsson; Anders Beckman; Kristina Johnell; Per Hjerpe; L Råstam; K Larsen Journal: J Epidemiol Community Health Date: 2006-04 Impact factor: 3.710
Authors: Bruce L Wilkoff; James R Cook; Andrew E Epstein; H Leon Greene; Alfred P Hallstrom; Henry Hsia; Steven P Kutalek; Arjun Sharma Journal: JAMA Date: 2002-12-25 Impact factor: 56.272
Authors: Pamela N Peterson; Melissa A Greiner; Laura G Qualls; Sana M Al-Khatib; Jeptha P Curtis; Gregg C Fonarow; Stephen C Hammill; Paul A Heidenreich; Bradley G Hammill; Jonathan P Piccini; Adrian F Hernandez; Lesley H Curtis; Frederick A Masoudi Journal: JAMA Date: 2013-08-14 Impact factor: 56.272
Authors: Ryan T Borne; Tiffany Randolph; Yongfei Wang; Jeptha P Curtis; Pamela N Peterson; Frederick A Masoudi; Amneet Sandhu; Matthew M Zipse; Kevin Thomas; Valentina Kutyifa; Nihar R Desai; Yong-Mei Cha; Jonathan C Hsu; Andrea M Russo Journal: JAMA Netw Open Date: 2019-10-02